---
title: "Hematology Clinical Research Feed | MedicHelpline"
specialty: "Hematology"
specialty_slug: "hematology"
canonical_url: "https://medichelpline.com/clinical-feed/hematology"
content_type: "clinical_feed_specialty"
page: 1
articles_in_batch: 30
generated_at: "2026-09-05T23:52:16.169Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Hematology — Clinical Research Feed
## Specialty Overview: Hematology
Latest peer-reviewed clinical trials, guidelines, and observational research in **Hematology**, indexed and structured for clinical intelligence and AI reasoning.
## Latest Hematology Publications
### 1. [Tirzepatide preserves HSPC cycling and reduces inflammatory Ly6Chi CCR2+ monocytes during weight l](https://medichelpline.com/clinical-feed/biorxiv-2-tirzepatide-preserves-hematopoietic-stem-and-progenitor-cycling-while.md)
- **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-09-04
- **Detail Markdown URL:** [Tirzepatide preserves HSPC cycling and reduces inflammatory Ly6Chi CCR2+ monocytes during weight l](https://medichelpline.com/clinical-feed/biorxiv-2-tirzepatide-preserves-hematopoietic-stem-and-progenitor-cycling-while.md)

> **Executive GIST:** - Obesity drives expansion of **myeloid progenitors**, increased **myelopoiesis**, and elevated monocyte production in mice. Weight loss can reduce this inflammatory state, but effects vary by weight-loss modality. - This study compared lean mice, obese mice, and weight-reduced (WL) mice achieving matched body weight loss via either **tirzepatide** treatment or caloric restriction (CR). - Caloric restriction produced broad multilineage **cytopenias**, indicating generalized suppression of hematopoiesis after WL by CR. - Tirzepatide-treated, weight-matched mice retained peripheral blood lineages while selectively lowering classical **Ly6Chi CCR2+ monocytes** rather than causing broad cytopenias. - Single-cell mRNA sequencing of bone marrow hematopoietic stem/progenitor cells (**HSPCs**) and mature blood mononuclear cells revealed distinct transcriptional programs between CR and tirzepatide groups. - CR-HSPCs showed suppression of gene sets linked to **nutrient sensing**, **proliferation**, and **oxidative phosphorylation (OXPHOS)**, with lower inferred cell-cycle activity compared with obese or lean controls. - Tirzepatide-HSPCs partially attenuated these CR-associated suppressive changes, preserving progenitor cycling and activity. - Across progressive differentiation from HSPCs to mature monocytes, tirzepatide increasingly suppressed **OXPHOS** gene programs and shifted the maturation trajectory away from classical monocytes. - After six weeks off tirzepatide with weight regain, Ly6Chi CCR2+ monocyte numbers returned to levels observed in obese mice, indicating the effect on classical monocytes is reversible and linked to ongoing treatment or weight status. - Authors conclude tirzepatide can uncouple weight loss from the broad hematopoietic suppression seen with CR by preserving progenitor activity while selectively remodeling inflammatory/classical monocytes, implicating classical monocytes as an effector cell population mediating reduced obesity-associated inflammation. - Competing interest note: JR reported multiple industry affiliations; other authors reported no competing interests. Funding sources were declared from NIH and a foundation in the source text.

### 2. [T lymphocytes and natural killer cells in myelodysplastic syndromes: review overview and access no](https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-t-lymphocytes-and-natural-killer-cells-in-myelodysplastic-syndromes-function.md)
- **Source:** Frontiers in Immunology | **Published:** 2026-09-04
- **Detail Markdown URL:** [T lymphocytes and natural killer cells in myelodysplastic syndromes: review overview and access no](https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-t-lymphocytes-and-natural-killer-cells-in-myelodysplastic-syndromes-function.md)

> **Executive GIST:** - The provided source page contains site navigation, journal sections, and metadata but does not include the full review text on **T lymphocytes**, **natural killer (NK) cells**, and **myelodysplastic syndromes (MDS)**. Details of study findings, mechanisms, or therapeutic recommendations were not reported on the captured page. - The page identifies the article as a REVIEW in Frontiers in Immunology and links to the journal and article landing pages, but the main article body is absent from the captured content. - The site content lists journal sections relevant to the topic (for example, **T Cell Biology** and **NK and Innate Lymphoid Cell Biology**) but offers no article-specific subsections, figures, or conclusions. - No author names, abstract, introduction, methods, results, discussion, or references were present in the captured source. Specific data, experimental results, or clinical recommendations therefore cannot be summarized or paraphrased. - Because the source capture is limited to navigation and front-matter, any claims about immune cell function, dysfunction, or therapeutic potential in MDS would be speculative and are not included. - Clinicians and researchers interested in the review should consult the journal landing page or the full article URL to retrieve the full text. The captured page provides links and a DOI-style path that can assist retrieval but did not include full-article content in the provided source. - When the full article is retrieved, summary points to look for include: characterization of **T lymphocyte** subsets in MDS, NK cell phenotypes and cytotoxicity, immune dysregulation mechanisms in bone marrow, and immunotherapeutic strategies tested or proposed for MDS. - The absence of the article body in the source is a limitation of the capture rather than an indication that the article lacks clinical content. Full appraisal requires reading the complete review on Frontiers in Immunology.

### 3. [Mean Platelet Volume and Disease Severity in Paediatric Sickle Cell Anaemia in Kwara State, Nigeria](https://medichelpline.com/clinical-feed/medrxiv-18-evaluating-mean-platelet-volume-in-relation-to-disease-severity-in-paediatric.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02
- **Detail Markdown URL:** [Mean Platelet Volume and Disease Severity in Paediatric Sickle Cell Anaemia in Kwara State, Nigeria](https://medichelpline.com/clinical-feed/medrxiv-18-evaluating-mean-platelet-volume-in-relation-to-disease-severity-in-paediatric.md)

> **Executive GIST:** - This cross-sectional hospital study evaluated the relationship between **mean platelet volume (MPV)** and disease severity in 51 clinically stable children with confirmed **sickle cell anaemia (SCA)** in Ilorin, Kwara State, Nigeria. - Disease severity was classified using a composite clinical and laboratory scoring system adapted from a previously described method; participants were grouped as mild (14, 27.5%), moderate (33, 64.7%), or severe (4, 7.8%). - Complete blood counts including MPV were measured on a Rayto RT-7600 automated haematology analyser; mean MPV was 9.34 ± 0.76 fL (range 8.0–11.2 fL). - Pearson correlation between MPV and severity score showed a weak positive, non-significant linear relationship (r = 0.231, p = 0.103). - Spearman rank analysis found a weak positive monotonic association between MPV and severity (rho = 0.286, p = 0.042), indicating inconsistent evidence across statistical approaches. - Simple linear regression showed MPV explained 5.3% of the variation in severity score (R2 = 0.053, p = 0.103). - MPV did not differ significantly across the three severity categories (Kruskal–Wallis H = 2.163, p = 0.339). - MPV correlated inversely with haemoglobin (r = -0.556, p < 0.001) and positively with platelet count (r = 0.307, p = 0.029). - Authors conclude that MPV shows a weak relationship with disease severity and, given limited explained variance and absence of significant category differences, is not supported as a standalone severity marker in this cohort. - The study recommends larger longitudinal studies to further evaluate MPV’s role; ethical approval was obtained from the Kwara State Ministry of Health Ethics and Research Committee (Reference No. MOH/KS/EU/777/593).

### 4. [Benchmarking frontier LLMs on 1,477 hematology board-style MCQs: accuracy and failure patterns](https://medichelpline.com/clinical-feed/medrxiv-1-benchmarking-ten-frontier-large-language-models-on-1-477-board-style-multiple.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02
- **Detail Markdown URL:** [Benchmarking frontier LLMs on 1,477 hematology board-style MCQs: accuracy and failure patterns](https://medichelpline.com/clinical-feed/medrxiv-1-benchmarking-ten-frontier-large-language-models-on-1-477-board-style-multiple.md)

> **Executive GIST:** - Researchers benchmarked ten leading large language models (LLMs) on 1,477 board-style multiple-choice questions (MCQs) in hematology drawn from five publicly available educational datasets spanning nine disease areas and six clinical skill domains. - Models included both proprietary and open-weight LLMs across two generations; testing covered text-only and multimodal case vignettes. - Top mean accuracies on text-only items were achieved by **Claude Opus 5** (92.7%), **Gemini-3.1 Pro** (91.4%), **Gemini-3.6 Flash** (91.0%) and **GPT-5.6 Sol** (89.9%). - On multimodal items, reported mean accuracies for these models were lower: Claude Opus 5 (76.9%), Gemini-3.1 Pro (78.7%), Gemini-3.6 Flash (74.8%) and GPT-5.6 Sol (76.7%). - Accuracy correlated significantly with **model size** for both text-only and multimodal MCQs. - Performance gains between model generations were largest for open-weight models; proprietary models showed only marginal generational improvements. - Error analysis revealed that top-performing models shared highly concordant failure patterns, indicating common limitations on challenging cases rather than idiosyncratic errors. - Authors conclude frontier LLMs demonstrate substantial specialist **hematology** knowledge across subspecialties and clinical skills, but caution that continuous expert-on-the-loop monitoring is essential despite high accuracy on board-style questions. - Data sources used were publicly available BSH MCQ, BSH EMQ, BSH Case Reports, ASH Hematopoiesis Case Studies, and EBMT Case of the Month; no new patient data or identifiable information were used. - Funding was declared from German Cancer Aid; competing interests by several authors were reported as detailed in the source.

### 5. [Slow Erythrocyte Sedimentation Rate: Biophysical insights, new parameters and clinical uses](https://medichelpline.com/clinical-feed/medrxiv-14-too-slow-erythrocyte-sedimentation-rate-deeper-biophysical-understanding-novel.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-01
- **Detail Markdown URL:** [Slow Erythrocyte Sedimentation Rate: Biophysical insights, new parameters and clinical uses](https://medichelpline.com/clinical-feed/medrxiv-14-too-slow-erythrocyte-sedimentation-rate-deeper-biophysical-understanding-novel.md)

> **Executive GIST:** - The erythrocyte sedimentation rate (**ESR**) is a longstanding, non-specific laboratory marker of inflammation based on red blood cell settling. - Recent work reframes ESR as the collapse of a percolating **erythrocyte gel**, improving the biophysical understanding of the process. - The study identifies multiple clinical conditions associated with a systematically **slow ESR**, including **sickle cell disease**, neuroacanthocytosis syndromes, and chronic mountain sickness. - Authors combined empirical measurements with physical modelling to derive more accurate and informative ESR-derived parameters. - From these improvements they introduce an enhanced metric, termed **supraESR**, which is calculated from existing, easily automated ESR measurements. - The **supraESR** is presented as a low-cost diagnostic parameter potentially useful for population screening, notably to detect **neuroacanthocytosis syndrome**, previously identifiable only through complex tests. - Ethical approval was provided by the Ethics committee of the Aerztekammer des Saarlandes (IRB number 51/18); patient consent and appropriate reporting standards were observed. - All data from the study are available on reasonable request to the authors; authors declared no competing interests. - Funders included Saarland University, Hermann und Lilly Schilling-Stiftung, Grenoble Alpes University foundation, and the French National Research Agency (ANR) as listed by the authors. - The preprint is available on medRxiv (posted September 01, 2026) and the authors state code/data availability in supplementary material or by request.

### 6. [HDAC6 regulates endothelial-to-mesenchymal transition and delays thrombus resolution in venous thr](https://medichelpline.com/clinical-feed/biorxiv-22-hdac6-is-a-novel-regulator-of-endothelial-to-mesenchymal-transition-in-venous.md)
- **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-09-01
- **Detail Markdown URL:** [HDAC6 regulates endothelial-to-mesenchymal transition and delays thrombus resolution in venous thr](https://medichelpline.com/clinical-feed/biorxiv-22-hdac6-is-a-novel-regulator-of-endothelial-to-mesenchymal-transition-in-venous.md)

> **Executive GIST:** - Venous thromboembolism (VTE) involves thrombus formation and vein wall remodeling; fibrosis may result from **endothelial-to-mesenchymal transition (EndMT)** driven by loss of endothelial markers and gain of mesenchymal markers. - Transforming growth factor beta (**TGFβ**) is a potent inducer of EndMT and impairs thrombus resolution in chronic thromboembolic pulmonary hypertension; molecular regulators of TGFβ signaling in VTE were previously unclear. - The authors hypothesized that epigenetic regulators control TGFβ signaling in endothelial cells and promote EndMT and vascular fibrosis. - The study investigated the role of histone deacetylase 6 (**HDAC6**) using in vitro endothelial cell experiments and an in vivo experimental VTE model, and analyzed public RNAseq datasets to support findings. - In vitro, endothelial cells treated with TGFβ and thrombin upregulated mesenchymal markers calponin and **transgelin**; pharmacological inhibition of HDAC6 with TCS20b prevented these increases. - TGFβ effects were mediated via ERK1/2 activation and HDAC6 activation according to the reported molecular analyses. - In vivo, treatment with the specific HDAC6 inhibitor **tubastatin A** reduced thrombus size seven days after surgery compared with controls; treatment durations reported ranged from 7 to 21 days. - Reduced expression of the EndMT marker transgelin in endothelial cells was observed in animals treated with HDAC6 inhibition relative to controls. - The splice isoform **FN1-EDA** was shown to be associated with EndMT, regulated by HDAC6 in vitro, linked to thrombosis in the analyzed RNAseq dataset, and potentially associated with recurrent DVT in patients. - Statistical analyses used two-way ANOVA with Tukey’s multiple comparisons for within-group and treatment differences. - The authors conclude that **HDAC6** regulates EndMT in venous thrombosis, impairs thrombus resolution, and controls expression of FN1-EDA, suggesting HDAC6 as a potential therapeutic target to reduce risk of recurrent VTE. - Funding sources and competing interests: the study declared funding by Fondation du Souffle and Fédération française de cardiologie; authors declared no competing interests.

### 7. [Distinct Proteomic Programs and Disease Risks Linked to Age-Related Clonal Hematopoiesis and Mosai](https://medichelpline.com/clinical-feed/medrxiv-3-age-related-clonal-hematopoiesis-and-mosaic-sex-chromosome-loss-define-distinct.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-31
- **Detail Markdown URL:** [Distinct Proteomic Programs and Disease Risks Linked to Age-Related Clonal Hematopoiesis and Mosai](https://medichelpline.com/clinical-feed/medrxiv-3-age-related-clonal-hematopoiesis-and-mosaic-sex-chromosome-loss-define-distinct.md)

> **Executive GIST:** - This UK Biobank analysis evaluated age-related hematopoietic clones and sex chromosome mosaicism in 450,587 participants, with plasma proteomics available for 46,324 individuals. - The study compared **clonal hematopoiesis** of indeterminate potential (CHIP) and mosaic loss of chromosome Y (**mLOY**) or X (**mLOX**) across ageing, incident disease, and circulating proteins. - Although CHIP, mLOY and mLOX all increase with age, they were associated with different disease spectra rather than representing a single ageing signature. - **Non-DNMT3A CHIP** (CHIP excluding DNMT3A-mutant clones) associated with a broad multisystem disease burden. - **mLOY** showed a more focused pattern of disease associations, notably respiratory, musculoskeletal and cardiovascular conditions. - **mLOX** did not show broad age-related disease links in these analyses. - Clone burden (extent of mosaicism or CHIP clone size) mapped to distinct circulating proteomic programs: mLOY linked to pathways of neutrophil degranulation and extracellular matrix remodeling; non-DNMT3A CHIP to myeloid immune regulation; and mLOX unexpectedly to cytotoxic lymphocyte and NK-cell response signatures. - Mendelian randomization analyses supported selected protein–disease relationships identified in the proteomic mapping. - The authors conclude that age-related hematopoietic clones are not interchangeable markers of ageing but define alteration-specific systemic programs and disease vulnerabilities. - Ethical and data access notes: analyses used UK Biobank data under application 170256; UK Biobank approval and participant consent were documented.

### 8. [Germline and Somatic Variants Independently Shape Risk and Enable Stratification in Immune Cytopen](https://medichelpline.com/clinical-feed/medrxiv-14-rare-and-common-germline-and-somatic-variants-shape-immune-cytopenia-risk-and.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-31
- **Detail Markdown URL:** [Germline and Somatic Variants Independently Shape Risk and Enable Stratification in Immune Cytopen](https://medichelpline.com/clinical-feed/medrxiv-14-rare-and-common-germline-and-somatic-variants-shape-immune-cytopenia-risk-and.md)

> **Executive GIST:** - The study analyzed the genetic contributors to **immune cytopenia** using whole-genome sequencing from two large biobanks (UK Biobank and All of Us). - Four classes of genetic variation were evaluated: rare germline variants in **inherited error of immunity** genes, common germline variants linked to **systemic lupus erythematosus** (SLE), somatic variants associated with hematological malignancies, and somatic variants underlying **clonal hematopoiesis**. - Each of the four variant types independently increased risk for immune cytopenia; their respective contributions and interactions were systematically assessed across cohorts. - Carriers of variants in some autosomal recessive inherited-immunity genes showed elevated immune cytopenia risk. - A polygenic or common-variant risk for SLE also conferred increased immune cytopenia risk in the studied populations. - Overall, between one-third and one-half of patients with immune cytopenia carried at least one of the four investigated genetic risk variant types. - Combining the four genetic risk categories enabled risk stratification: in the general population the estimated 10-year incidence ranged from 0.08% in the lowest-risk group to 1.5% in the highest-risk group. - Risk stratification was demonstrated both in general-population samples and in higher-risk subgroups. - Data supporting the analysis came from licensed access to UK Biobank and All of Us; code for analyses is available on the authors’ GitHub repository. - Ethical approvals and participant consent were obtained; one author disclosed unrelated industry funding and a research scholarship; other authors declared no competing financial interests.

### 9. [Molecular landscape and ELN risk stratification in acute myeloid leukemia: findings from the REFOR](https://medichelpline.com/clinical-feed/medrxiv-0-molecular-landscape-and-risk-stratification-in-acute-myeloid-leukemia-insights.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-31
- **Detail Markdown URL:** [Molecular landscape and ELN risk stratification in acute myeloid leukemia: findings from the REFOR](https://medichelpline.com/clinical-feed/medrxiv-0-molecular-landscape-and-risk-stratification-in-acute-myeloid-leukemia-insights.md)

> **Executive GIST:** - The REFORM-AML study reports clinicopathological, genomic, and outcome data from a Danish, real-world cohort of 2,512 acute myeloid leukemia (**AML**) patients identified between 2015 and 2022. - Next-generation sequencing (**NGS**) data were available for 33.8% of patients (NGS+). - Among patients aged ≤70 years, baseline characteristics and outcomes were similar between NGS+ and NGS- groups. - In patients >70 years, a greater proportion of NGS+ patients received intensive treatment, yet survival among intensively treated older patients did not differ by NGS status. - The frequency and distribution of somatic mutations varied with age and sex; older age and male sex were associated with higher frequencies of **adverse-risk gene mutations**. - In intensively treated NGS+ patients, ELN2017 stratified 5-year overall survival (OS) at 58.4% (favorable), 43.4% (intermediate), and 28.2% (adverse); hazard ratios (HRs) versus intermediate risk were 0.63 for favorable and 1.45 for adverse. - Using ELN2022 in the same subgroup produced 5-year OS of 56.9% (favorable), 51.8% (intermediate), and 29.7% (adverse) with HRs of 0.78 and 1.86 versus intermediate. - Time-dependent comparative analysis showed **ELN2017** and **ELN2022** had comparable predictive performance for overall survival in intensively treated, NGS+ patients. - The authors conclude that intensively treated AML outcomes were comparable regardless of NGS availability, supporting the representativeness of the REFORM-AML database for the Danish AML population. - Study approvals were obtained from the North Denmark Region (IDs: 2021-011009 and 2021-197); patient consent was waived according to Danish legislation. - Data cannot be shared directly under Danish law but are available on application; funding was declared from the Danish Cancer Society. - Competing interests were reported for several authors, including consultancy/advisory roles, travel grants, speaker fees, and research funding as detailed in the manuscript.

### 10. [FDA approves Mimrylo (rusfertide) — weekly injection for polycythemia vera](https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-approves-protagonist-and-takeda-s-drug-for-rare-blood-cancer.md)
- **Source:** STAT News | **Published:** 2026-08-30
- **Detail Markdown URL:** [FDA approves Mimrylo (rusfertide) — weekly injection for polycythemia vera](https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-approves-protagonist-and-takeda-s-drug-for-rare-blood-cancer.md)

> **Executive GIST:** - The FDA approved **rusfertide**, branded as **Mimrylo**, for the treatment of **polycythemia vera**. - The drug was developed by Protagonist Therapeutics and will be marketed by Takeda under the Mimrylo name. - Mimrylo is given as a **weekly injection**. - Polycythemia vera is described as a chronic, slow-growing blood cancer characterized by overproduction of red blood cells that increases risk of heart attack, stroke, and blood clots. - STAT reports the approval and cites an FDA press announcement; the article indicates additional details of the story are behind a STAT+ paywall. - The published story states the FDA described the product as a new kind of treatment for this rare disorder. - The source article does not report specific clinical trial results, safety and adverse event data, comparative efficacy, recommended dosing beyond weekly administration, pricing, or an expected commercial launch timeline. - Regulatory and company statements referenced include an FDA approval announcement and identification of Protagonist as developer and Takeda as the commercial partner; the STAT piece is authored by Adam Feuerstein and dated Aug. 30, 2026. - Further details and fuller reporting were available only to STAT+ subscribers per the source article.

### 11. [Perturb‑seq reveals co‑regulated gene programs governing hematopoietic stem and progenitor cells](https://medichelpline.com/clinical-feed/biorxiv-16-perturb-seq-identifies-co-regulated-gene-programs-shaping-hematopoietic-stem.md)
- **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-08-29
- **Detail Markdown URL:** [Perturb‑seq reveals co‑regulated gene programs governing hematopoietic stem and progenitor cells](https://medichelpline.com/clinical-feed/biorxiv-16-perturb-seq-identifies-co-regulated-gene-programs-shaping-hematopoietic-stem.md)

> **Executive GIST:** - The study applied **Perturb-seq** with CRISPRi to primary mouse **hematopoietic stem and progenitor cells (HSPCs)** to map transcriptional consequences of genetic perturbations. 520 genes were targeted across the screen. - The authors developed an analytical workflow to disentangle perturbation-driven shifts in cell-state abundance and clonal heterogeneity from local, cell-state–specific transcriptional effects of each perturbation. - From these local perturbation signatures the team defined 19 **gene regulatory programs (GRPs)** based on co-regulation in response to perturbation rather than simple co-expression or manual curation. - The identified GRPs align with recognizable cell-biological processes such as cell cycle control, stress responses and lineage priming that are relevant to stem cell function. - Decomposition of independent gene expression datasets into GRP activity showed that program activity correlates with functional stem-cell phenotypes, including clonal output after transplantation. - GRP activity also associated with clinical phenotypes in retrospective acute myeloid leukemia (**AML**) cohorts, including survival and drug response, indicating potential translational relevance. - The work positions perturbation-derived co-regulation programs as an interpretable framework linking genetic regulators, cell-biological processes and stem-cell-associated phenotypes. - Data and code supporting the study are made available through figshare links and a GitHub repository (veltenlab/hsc19).

### 12. [FDA Approves Mimrylo (rusfertide) for Polycythemia Vera — First-in-Class Hepcidin Mimetic](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-approves-first-drug-of-its-kind-for-polycythemia-vera-a-rare-blood-disorder.md)
- **Source:** FDA News Releases | **Published:** 2026-08-28
- **Detail Markdown URL:** [FDA Approves Mimrylo (rusfertide) for Polycythemia Vera — First-in-Class Hepcidin Mimetic](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-approves-first-drug-of-its-kind-for-polycythemia-vera-a-rare-blood-disorder.md)

> **Executive GIST:** - The FDA approved Mimrylo (rusfertide) on August 28, 2026, for treatment of adults with **polycythemia vera**, a rare blood disorder characterized by excessive red blood cell production. - Mimrylo is described as a first-in-class therapy that **mimics hepcidin**, the hormone that regulates iron, thereby limiting iron availability for red blood cell synthesis. - The drug is intended for patients whose disease has not been adequately controlled with existing therapies and who require frequent phlebotomies. - Approval was based on the VERIFY phase 3 randomized, double-blind, placebo-controlled trial of 293 adults requiring frequent phlebotomies despite standard-of-care therapy. - In VERIFY, patients received subcutaneous Mimrylo starting at 19 mg once weekly with titration to maintain **hematocrit** below 45%. - The primary efficacy measure reported was the proportion of patients who did not meet criteria for phlebotomy between weeks 20 and 32. - Results showed 76.9% of Mimrylo-treated patients required no phlebotomy during the 32-week period versus 32.9% on placebo. - The most common adverse reactions in the trial were injection site reactions and anemia. - Mimrylo received priority review and the approval was granted to Takeda Pharmaceuticals America, Inc. - The FDA emphasized that maintaining hematocrit below 45% reduces cardiovascular risks associated with polycythemia vera, such as thrombosis, stroke, and heart attack. - The FDA noted that phlebotomy remains a common intervention but that some patients continue to require frequent procedures despite treatment; Mimrylo provides an alternative mechanism targeting iron regulation. - Additional specific safety, dosing titration details beyond those summarized in the release were not reported in the source.

### 13. [Machine Learning Predicts Hospital-Acquired VTE Better Than Padua and IMPROVE](https://medichelpline.com/clinical-feed/medrxiv-13-beyond-padua-and-improve-machine-learning-outperforms-guideline-risk-scores-for.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-28
- **Detail Markdown URL:** [Machine Learning Predicts Hospital-Acquired VTE Better Than Padua and IMPROVE](https://medichelpline.com/clinical-feed/medrxiv-13-beyond-padua-and-improve-machine-learning-outperforms-guideline-risk-scores-for.md)

> **Executive GIST:** - The study evaluated machine learning models versus guideline scores (Padua, IMPROVE) to predict hospital-acquired **venous thromboembolism (VTE)** using MIMIC-IV admissions data. - Cohort comprised 399,624 adult admissions from MIMIC-IV (2008–2022), excluding prior-VTE admissions to focus on first-ever events; VTE events were ascertained from radiology report text using expert-benchmarked pipelines. - VTE incidence in the cohort was 1,915 admissions (0.479%). - Static models (logistic regression, **XGBoost**) used 57 features from the first 24 hours; dynamic landmark models used 92 time-updated features; a GRU sequence model was also tested. - Cross-validation fold-mean AUCs: **XGBoost** 0.8751 (95% CI 0.8705–0.8805), logistic regression 0.8428, Padua 0.6330. Out-of-fold inference showed statistically significant ΔAUC improvements of ML over Padua and IMPROVE (P 24 hours after admission and including prior-VTE admissions preserved the ML advantage over Padua (both P < 0.0005). - Authors conclude routine admission data–based ML models can substantially outperform Padua and IMPROVE; the static model computes within 24 hours and could augment manual assessment pending recalibration and external prospective validation. - The study used openly available MIMIC-IV and MIMIC-IV-Notes data; code and derived outputs are reported as available per the manuscript. No competing interests were declared.

### 14. [Per-patient-per-month costs and total NHS burden of higher-risk MDS treated with azacitidine in En](https://medichelpline.com/clinical-feed/bmj-open-16-health-system-burden-of-higher-risk-myelodysplastic-syndromes-in-england-a.md)
- **Source:** BMJ Open | **Published:** 2026-08-28
- **Detail Markdown URL:** [Per-patient-per-month costs and total NHS burden of higher-risk MDS treated with azacitidine in En](https://medichelpline.com/clinical-feed/bmj-open-16-health-system-burden-of-higher-risk-myelodysplastic-syndromes-in-england-a.md)

> **Executive GIST:** - This literature-based micro-costing study quantified phase-specific and total direct NHS provider costs for a non-curative management pathway of **higher-risk myelodysplastic syndromes (HR-MDS)** in England. - The analysis used published sources and publicly available 2024/2025 English unit costs; no individual-patient data were used. - A base-case patient pathway included diagnostic work-up at month 0 (with genomics), 12 cycles of **azacitidine** (7 days per 28-day cycle), 5 months of post-hypomethylating agent (**HMA**) failure supportive care, and 1 month of terminal care. - Patients undergoing allogeneic haematopoietic stem cell transplantation or transformation to acute myeloid leukaemia were excluded because their pathways differ. - Reported phase **per-patient-per-month (PPPM)** costs were: £8,721.58 during active azacitidine therapy; £5,399.58 after HMA failure; and £12,554.58 for hospital-dominant terminal care. - A one-off diagnostic work-up including genomics cost between £2,710 and £2,810. - The total cost of the base-case non-curative management pathway was £146,921 per patient. - An alternative pathway excluding genomic testing and assuming hospice-dominant terminal care reduced the total to approximately £136,840–£140,990 depending on hospice bed-day cost bounds. - The study found costs concentrated in azacitidine acquisition and administration during active treatment, transfusions and admissions after HMA failure, and terminal care setting-dependent costs. - Phase-specific PPPM estimates are intended to inform UK budget-impact analyses, service planning and future economic models but require local validation and scenario testing; the authors caution against interpreting the comparison to an NICE estimate as model validation due to structural and population differences.

### 15. [Ibrutinib in Early-Stage CLL: Genetic Risk Factors and Outcomes — GCLLSG CLL12 Trial Summary](https://medichelpline.com/clinical-feed/pubmed-42322115.md)
- **Source:** PubMed / NCBI | **Published:** 2026-08-27 | DOI: [10.1182/blood.2025032806](https://doi.org/10.1182%2Fblood.2025032806)
- **Detail Markdown URL:** [Ibrutinib in Early-Stage CLL: Genetic Risk Factors and Outcomes — GCLLSG CLL12 Trial Summary](https://medichelpline.com/clinical-feed/pubmed-42322115.md)

> **Executive GIST:** - This PubMed citation reports a randomized controlled trial titled **Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial**, published in Blood (2026 Aug 27;148[9]:1108-1114). - The article is listed as a free article with PMID 42322115 and DOI 10.1182/blood.2025032806. - The author list and multi-center German affiliations are provided, including the Division of Chronic Lymphocytic Leukaemia at Ulm University and members of the German CLL Study Group. - The citation identifies the study as part of the GCLLSG CLL12 trial and focuses on **Ibrutinib**, genetic risk factors, and treatment outcomes in early-stage **CLL**. - The PubMed record includes links to full-text sources (Blood and other publishers) but the extracted page content provided here does not include study methods, patient numbers, genetic markers assessed, efficacy outcomes, safety data, or statistical results. - Because the source text shown is the PubMed landing page and is truncated, specific trial results, methodology, and numerical findings were not reported in the provided source and must be obtained from the full text for clinical interpretation. - Key metadata available: authors, affiliations, publication date, journal, article type (Randomized Controlled Trial), PMID, DOI, and free-article status. - Clinical readers should consult the full published article or supplementary materials for detailed methods, definitions of genetic risk factors, outcome measures, and the trial’s conclusions before applying findings to practice.

### 16. [Daratumumab‑VCD for Newly Diagnosed AL Amyloidosis: ANDROMEDA Final Survival Analysis (Blood 2026)](https://medichelpline.com/clinical-feed/pubmed-42118698.md)
- **Source:** PubMed / NCBI | **Published:** 2026-08-27 | DOI: [10.1182/blood.2025032099](https://doi.org/10.1182%2Fblood.2025032099)
- **Detail Markdown URL:** [Daratumumab‑VCD for Newly Diagnosed AL Amyloidosis: ANDROMEDA Final Survival Analysis (Blood 2026)](https://medichelpline.com/clinical-feed/pubmed-42118698.md)

> **Executive GIST:** - The publication reports the final survival analysis of the ANDROMEDA clinical trial evaluating **daratumumab** combined with bortezomib, cyclophosphamide and dexamethasone (VCD) in newly diagnosed amyloidosis (AL amyloidosis). - The article is a Clinical Trial report published in Blood on 2026 Aug 27 (Volume 148, Issue 9) with DOI 10.1182/blood.2025032099. - The paper lists a large, international group of investigators and collaborating centers under the ANDROMEDA Trial Investigators, indicating a multicenter effort across Europe, North America, Asia and other regions. - coauthors and affiliations include specialist amyloidosis and hematology centers and multiple academic institutions; several authors are affiliated with Johnson & Johnson. - The article is identified as the final survival analysis, implying longitudinal follow-up of trial participants to assess survival outcomes. - The PubMed record and abstract header are provided in the source, but the supplied source text does not include numerical results, survival statistics, hazard ratios, p values, subgroup outcomes, safety data, or explicit methodological details (randomization, sample size, eligibility criteria, follow‑up duration, or statistical methods). - Because the source text provided here is limited to the PubMed landing page and citation metadata, specific trial results, effect sizes, adverse events, and detailed conclusions are not reported in this source excerpt. - Any detailed interpretation of efficacy, safety, or practice implications cannot be drawn from the supplied text; readers should consult the full Blood article or full text links for complete data and prespecified analyses. - The record links to full-text sources (Blood/Silverchair, Elsevier) and notes the ANDROMEDA Trial Investigators and multiple collaborating authors and institutions, confirming broad investigator participation and industry collaboration in trial conduct or support.

### 17. [Sequential conditioning for hematopoietic stem cell transplant in elderly high-risk myeloid malign](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-sequential-conditioning-in-hematopoietic-stem-cell-transplantation-in-elderly.md)
- **Source:** Frontiers in Immunology | **Published:** 2026-08-26
- **Detail Markdown URL:** [Sequential conditioning for hematopoietic stem cell transplant in elderly high-risk myeloid malign](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-sequential-conditioning-in-hematopoietic-stem-cell-transplantation-in-elderly.md)

> **Executive GIST:** - The provided source page and metadata indicate an article titled about **sequential conditioning** in **hematopoietic stem cell transplantation** (HSCT) for elderly patients with high-risk myeloid blood cancers, analyzing long-term survival, disease control, and immune recovery across donor types in a matched-pair analysis. - The source JINA body contains only Frontiers website navigation and page scaffolding; the article text, methods, numerical results, and conclusions were not available in the provided source content. - From the title alone, the study scope likely addresses outcomes after HSCT in an older, high-risk myeloid malignancy population, comparing donor types and evaluating **long-term survival**, **disease control**, and **immune reconstitution** following a sequential conditioning regimen. - The phrase “matched-pair analysis” in the title indicates a comparative design using matched pairs to control for confounders when comparing donor types or treatment groups; exact matching criteria were not reported in the source content. - Important details missing from the provided source include patient numbers, age range, diagnostic subtypes, conditioning regimen components and schedule, donor categories (related, unrelated, haploidentical, cord blood, etc.), follow-up duration, survival rates (overall survival, disease-free survival), relapse incidence, graft-versus-host disease rates, immune recovery metrics, and statistical analyses. - Because the article text and data were not present in the supplied content, no study-specific outcomes, effect sizes, or recommendations can be summarized or inferred without risking invention of facts. - Users seeking the full study should consult the original Frontiers in Immunology article at the provided URL for complete methods, results, tables, and authors’ conclusions.

### 18. [ABO and RhD Frequencies in Patients vs Blood Donors: Implications for the U.S. Blood Supply](https://medichelpline.com/clinical-feed/plos-one-18-abo-and-rhd-blood-group-antigen-frequencies-in-patients-and-blood-donors.md)
- **Source:** PLOS ONE (Medicine) | **Published:** 2026-08-25
- **Detail Markdown URL:** [ABO and RhD Frequencies in Patients vs Blood Donors: Implications for the U.S. Blood Supply](https://medichelpline.com/clinical-feed/plos-one-18-abo-and-rhd-blood-group-antigen-frequencies-in-patients-and-blood-donors.md)

> **Executive GIST:** - This multi-center retrospective study compared **ABO** and **RhD** antigen frequencies among 467,748 patients from five University of California medical centers, 719,211 California blood donors, and 7,449,831 US blood donors typed over a five-year period. - Overall group frequencies differed between patients and donors: Group O represented 46.2% of patients, 50.8% of California donors, and 48.8% of US donors; Group A was 35.8% of patients, 32.1% of California donors, and 36.0% of US donors; Group B was 14.1% of patients, 13.0% of California donors, and 11.3% of US donors; Group AB was 3.9%, 4.1%, and 3.9%, respectively. - **RhD-positive** prevalence was 90.0% among patients, 88.4% among California donors, and 83.0% among US donors. - The study found statistically significant variation in patient ABO/RhD frequencies by institution (site), age, and sex, and overall differences between patient and donor populations. - Methods: aggregated, de-identified ABO/RhD typing and demographic data were extracted from electronic health records and blood establishment systems for unique individuals between March 1, 2018 and February 28, 2023; donors were from American Red Cross datasets covering California and the broader US. - Race was categorized following OMB categories in effect until March 2024; race was self-reported and mapped to OMB categories, with non-matching responses classified as Other or Not Reported/Unknown. - Testing used standard automated agglutination or solid-phase techniques with reflex tube testing as needed; indeterminate typings were excluded. - Analyses used descriptive statistics and Pearson’s chi-squared tests to compare distributions. Software included Microsoft Excel and R. - The authors conclude that patient and donor ABO/RhD distributions are not aligned, which may have implications for donor recruitment, inventory management, and policy; they recommend further investigation into the consequences of this misalignment. - Data and supporting information are available with the publication; the study reports no specific funding and no competing interests.

### 19. [Genetic, Geographic, and Phenotypic Correlates of Somatic Passenger Mutations in Blood from 791K G](https://medichelpline.com/clinical-feed/medrxiv-2-multi-ancestry-analysis-of-791k-whole-genomes-reveals-the-genetic-geographic.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-25
- **Detail Markdown URL:** [Genetic, Geographic, and Phenotypic Correlates of Somatic Passenger Mutations in Blood from 791K G](https://medichelpline.com/clinical-feed/medrxiv-2-multi-ancestry-analysis-of-791k-whole-genomes-reveals-the-genetic-geographic.md)

> **Executive GIST:** - The study used **passenger mutation burden** as a quantitative, driver-agnostic phenotype to study clonal hematopoiesis (CH) across 791,067 blood whole-genome sequences from UK Biobank and the All of Us Research Program. - Multi-ancestry genome-wide meta-analysis identified 81 loci associated with passenger mutation burden, including 42 novel loci reported in this analysis. - Rare-variant analyses implicated specific genes including **MBD2**, **PRKACB**, and **PUF60**, highlighting epigenetic and transcriptional regulators of clonal fitness. - Common and rare germline associations converged with canonical CH driver pathways regulating **DNA methylation**, **chromatin**, **RNA splicing**, and **genome maintenance**. - Sex- and ancestry-stratified analyses revealed both shared and population-specific genetic determinants of CH; some loci were only detected in stratified analyses and not in pooled analyses. - Associated variants were concentrated in regulatory elements active in **hematopoietic stem and progenitor cells (HSPCs)**, linking germline associations to relevant cell states and lineages. - Phenome-wide analyses distinguished consequences of inherited CH liability from observed passenger burden: passenger burden strongly associated with incident hematologic malignancy and mortality, while germline risk showed additional nonhematologic associations. - Spatial modelling across U.S. regions demonstrated persistent geographic heterogeneity in passenger mutation burden that was incompletely explained by income, air quality, or chemotherapy prevalence, suggesting unmeasured environmental contributors. - The parallel analysis of two population-scale biobanks characterizes the multi-ancestry genetic architecture of CH and reveals convergence of germline and somatic variation on shared pathways governing clonal expansion in aging blood.

### 20. [Daratumumab and Minimal Residual Disease in CEPHEUS for Transplant-Ineligible Newly Diagnosed Mult](https://medichelpline.com/clinical-feed/pubmed-42234958.md)
- **Source:** PubMed / NCBI | **Published:** 2026-08-25 | DOI: [10.1182/bloodadvances.2026019937](https://doi.org/10.1182%2Fbloodadvances.2026019937)
- **Detail Markdown URL:** [Daratumumab and Minimal Residual Disease in CEPHEUS for Transplant-Ineligible Newly Diagnosed Mult](https://medichelpline.com/clinical-feed/pubmed-42234958.md)

> **Executive GIST:** - This item is a clinical trial report titled “Daratumumab in transplant-ineligible or -deferred newly diagnosed **multiple myeloma**: minimal residual disease in **CEPHEUS**,” published in Blood Advances (2026 Aug 25;10(16):5594-5606). - The trial focuses on the anti-CD38 monoclonal antibody **daratumumab** and assesses **minimal residual disease (MRD)** in the CEPHEUS study population of transplant-ineligible or transplant-deferred, newly diagnosed myeloma patients. - The PubMed record lists Sonja Zweegman and a large international multicenter author group; numerous academic and industry affiliations are reported. - Indexing and identifiers provided: PMID 42234958, PMCID PMC13495367, DOI 10.1182/bloodadvances.2026019937. - The PubMed entry designates the article as a Clinical Trial and links to a free full text at PubMed Central. - The excerpted PubMed record includes extensive author and affiliation information across international centers and involvement from Johnson & Johnson staff, but the excerpt does not report trial results, MRD rates, statistical outcomes, safety data, or detailed methods. - The abstract/body content and specific efficacy or safety findings were not included in the provided source excerpt; therefore numerical results, conclusions, and recommendations are not reported here. - For complete study methods, MRD measurement technique, primary and secondary endpoints, numerical outcomes, and authors’ conclusions, consult the full-text article at the provided PMCID/DOI links.

### 21. [Systemic racial barriers to blood donation for Black people in Canada: qualitative study](https://medichelpline.com/clinical-feed/cmaj-0-our-blood-is-not-pure-enough-a-qualitative-study-to-understand-systemic-racial.md)
- **Source:** CMAJ | **Published:** 2026-08-24
- **Detail Markdown URL:** [Systemic racial barriers to blood donation for Black people in Canada: qualitative study](https://medichelpline.com/clinical-feed/cmaj-0-our-blood-is-not-pure-enough-a-qualitative-study-to-understand-systemic-racial.md)

> **Executive GIST:** - The study explored barriers to **blood donation** among Black adults in Canada using semi-structured qualitative interviews conducted March–June 2023. - Researchers interviewed 42 Black adults (57.1% women) recruited via social media and Black-led community organizations across seven provinces. - Analysis followed Braun and Clarke’s 6-step thematic approach and used NVivo for coding; cultural safety and antiracist practices guided data collection. - Participants described 14 themes organized into 5 clusters: systemic and policy barriers, knowledge and awareness barriers, accessibility and practical barriers, social and cultural barriers, and psychological barriers. - Systemic and policy barriers were most frequently cited and included restrictive policies by **Canadian Blood Services** and **Héma-Québec**, institutional racism, and historical anti-Black discrimination that have fostered mistrust. - Knowledge gaps included lack of accessible information, perceptions that Black donors’ blood is underutilized, and outreach that excludes Black communities. - Accessibility barriers included few or inaccessible donation sites and financial constraints that make donation difficult for some participants. - Social and cultural barriers encompassed stigma, lack of representation among staff, and environments perceived as unwelcoming to Black donors. - Psychological barriers included common fears (needles) and widespread mistrust in health care and blood donation systems rooted in historical events such as the HIV/AIDS era and restrictive past deferral policies. - The authors link the donor deficit among Black people to clinical consequences—for example, limited availability of antigen-matched blood for patients with **sickle cell disease**, increasing alloimmunization risk. - The study calls for policy reform, inclusive communication, and partnership between blood organizations and Black communities to rebuild trust and improve donor diversity. - Recruitment continued until saturation; interviews lasted 24–38 minutes and were conducted in English or French by trained Black bilingual research assistants. - The Interdisciplinary Centre for Black Health at the University of Ottawa coordinated aspects of the study and provided culturally informed research infrastructure. - Specific operational or timeline details for policy changes, or precise counts of the 14 themes, beyond grouping into 5 clusters, are those reported in the source.

### 22. [Persistent Hypercoagulability and Characterization of Microclot Complexes in Long COVID](https://medichelpline.com/clinical-feed/medrxiv-17-persistent-hypercoagulability-and-further-characterization-of-microclot.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-23
- **Detail Markdown URL:** [Persistent Hypercoagulability and Characterization of Microclot Complexes in Long COVID](https://medichelpline.com/clinical-feed/medrxiv-17-persistent-hypercoagulability-and-further-characterization-of-microclot.md)

> **Executive GIST:** - This preprint reports that plasma from people with **Long COVID** shows persistent **hypercoagulability** on thromboelastography (TEG), with altered clotting kinetics despite unchanged maximal clot strength. - The study compared whole blood and platelet-poor plasma (PPP) from control (n=19) and Long COVID (n=20) participants using TEG and multiple microscopy and flow-cytometry probes. - Key TEG changes in Long COVID samples included shortened R, K and TMRTG and increased alpha-angle and MRTG, while MA and TTG were unchanged, implicating altered clot formation dynamics rather than increased clot strength. - Thioflavin-T (ThT)-positive **microclot complexes (FMCs)** were significantly increased in Long COVID across undiluted PPP, 10X diluted PPP, and resuspended PPP pellets; some ThT-positive material remained in the supernatant after centrifugation, indicating density heterogeneity. - Imaging flow cytometry and microscopy with co-staining (CD62P-PE, Hoechst 33342, CellMask Red, MPO, Congo Red) showed FMC heterogeneity: events containing leukocyte material were most abundant, platelet-derived material was elevated in Long COVID, and ThT-only, membrane-free amyloid events were identified. - The relative abundance by probe was leukocyte-derived > platelet-derived > ThT-positive FMCs, and the populations had distinct morphologies and size distributions. - The increased platelet-derived debris in PPP suggests ongoing platelet activity in Long COVID, while Congo Red positivity supports an amyloid nature for FMCs. - The authors conclude that an amyloid-dominated FMC population coexists with FMCs containing cellular material and that persistent soluble plasma constituents contribute to the hypercoagulable phenotype. - The study is a clinical preprint (not peer reviewed). Ethical approval was provided by Stellenbosch University HREC and samples were from an anonymized biorepository with informed consent. Data are available on reasonable request.

### 23. [DNMT3A-driven clonal hematopoiesis linked to heightened trained immunity and altered immune cell f](https://medichelpline.com/clinical-feed/medrxiv-11-association-between-dnmt3a-driven-clonal-hematopoiesis-trained-immunity-and.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-23
- **Detail Markdown URL:** [DNMT3A-driven clonal hematopoiesis linked to heightened trained immunity and altered immune cell f](https://medichelpline.com/clinical-feed/medrxiv-11-association-between-dnmt3a-driven-clonal-hematopoiesis-trained-immunity-and.md)

> **Executive GIST:** - This study examined links between **DNMT3A**-driven clonal hematopoiesis (CH) and the capacity to develop **trained immunity** in people with overweight and obesity. - From a previously characterized cohort of older individuals with overweight and obesity, researchers selected 17 individuals with CH due to **DNMT3A** mutations and 15 individuals without known clonal hematopoiesis driver mutations (CHDMs). - Immune profiling included flow cytometry, functional assays of monocytes and neutrophils, and in vitro trained immunity assays using **β-glucan** and oxidized LDL (oxLDL) as stimuli. - PBMCs from individuals with **DNMT3A** mutations showed lower ex vivo cytokine production capacity, corroborating earlier findings from this cohort. - Presence of **DNMT3A** CHDMs was associated with an increased trained immunity response to β-glucan and oxLDL, indicating higher susceptibility to developing a hyperresponsive trained monocyte phenotype. - Participants with **DNMT3A** mutations had higher proportions of CD10+ mature **neutrophils** and exhibited lower neutrophil myeloperoxidase (MPO) release after TLR2 stimulation. - The authors note convergent molecular mechanisms between clonal hematopoiesis and trained immunity, including the central regulatory role of **IL-1β** and involvement of epigenetic enzymes, and hypothesized CHDMs might predispose to enhanced trained immunity. - The study concludes that **DNMT3A** CHDMs are associated with increased capacity to build trained immunity and altered innate immune cell function in obesity, but states that the precise molecular mechanisms remain to be elucidated. - Ethical approval was obtained from the Radboud University Ethical Committee (NL72552.091.20; 2020-6135) and all participants gave written informed consent. Data are available on reasonable request. - Competing interests: most authors report no disclosures; one author is founder of companies named in the source. Funders included Hartstichting and IN CONTROL II; CVON2018-27.

### 24. [Plateau Hemoglobin Paradox: SpO2-Dependent Reversal of Hemoglobin Effect on Postoperative LOS at H](https://medichelpline.com/clinical-feed/medrxiv-0-the-plateau-hemoglobin-paradox-reversed-effect-of-hemoglobin-on-surgical.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-23
- **Detail Markdown URL:** [Plateau Hemoglobin Paradox: SpO2-Dependent Reversal of Hemoglobin Effect on Postoperative LOS at H](https://medichelpline.com/clinical-feed/medrxiv-0-the-plateau-hemoglobin-paradox-reversed-effect-of-hemoglobin-on-surgical.md)

> **Executive GIST:** - This retrospective single-center cohort study examined 612 adults undergoing elective laparoscopic cholecystectomy at Qinghai Red Cross Hospital (Xining, 2260 m) between 2018 and 2023. - The investigators tested whether preoperative **hemoglobin (Hb)** associations with postoperative **length of stay (LOS)** varied across arterial oxygen saturation (**SpO2**) strata. - Preoperative Hb ranged 82–233 g/L (mean 151.4 g/L) and SpO2 ranged 86%–99% (mean 94.6%). - SpO2 was predefined into three strata: low (<93%), mid (93%–95%), and high (≥96%). - Primary analysis used multivariable linear regression with an Hb × SpO2 interaction term adjusted for BMI, age, sex, and season; the interaction was significant (beta = -0.0095; P = .009). - The direction of the Hb effect on LOS reversed across SpO2 strata: in SpO2 ≥93% each 1 g/L higher Hb was associated with a 0.003-day longer LOS (P = .079), whereas in SpO2 <93% each 1 g/L higher Hb was associated with a 0.006-day shorter LOS. - In the mid-SpO2 stratum (n = 251), patients with Hb ≥180 g/L had longer LOS than those with lower Hb (1.88 vs 1.62 days; P = .001; effect size d = 0.54). - Five computational robustness analyses, including a leave-one-out approach, confirmed the Hb × SpO2 interaction (leave-one-out: 100% of 612 iterations P < .05). - The authors label the observed pattern the **"Plateau Hemoglobin Paradox"**: an SpO2-dependent reversal of Hb effect on postoperative LOS at high altitude. - The study is exploratory, single-center, and achieved reported statistical power of 0.754; the authors state findings require replication before clinical application.

### 25. [Whole-genome sequencing identifies rare coding variants and key genes associated with acute myeloi](https://medichelpline.com/clinical-feed/medrxiv-21-prioritizing-genes-and-rare-protein-coding-variants-in-acute-myeloid-leukemia.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-22
- **Detail Markdown URL:** [Whole-genome sequencing identifies rare coding variants and key genes associated with acute myeloi](https://medichelpline.com/clinical-feed/medrxiv-21-prioritizing-genes-and-rare-protein-coding-variants-in-acute-myeloid-leukemia.md)

> **Executive GIST:** - This preprint analyzes whole-genome sequencing from the All of Us Research Program to evaluate the contribution of **rare protein-coding variants** and common variants to risk of **acute myeloid leukemia (AML)**. - The study used a European-like ancestry sample with Ncases = 265 AML cases and Ncontrols = 169,706 controls for association testing. - Rare-variant set-based tests were performed with **SAIGE-GENE+**; single-variant tests were performed for common variants. - Four genes reached statistical significance in rare-variant tests after Bonferroni correction: **DNMT3A**, **TET2**, **SRSF2**, and **IDH2**. - The authors constructed rare-variant burden risk scores across multiple gene-sets to identify aggregated rare-variant effects linked to AML. - Gene-sets derived from Genomic Data Commons (GDC) whole-genome sequencing—one comprising genes with somatic mutations observed in AML and another with genes mutated across cancers—showed a statistically significant rare-variant burden after multiple-testing correction. - The data sources and tools used include the AoU Curated Data Repository (version 8), VEP v115 for annotation, GDC clinical and RNA-seq data, single-cell RNA-seq (GSE116256), and ClinVar; code and summary statistics are provided on GitHub subject to AoU reporting limits. - The study is a preprint (not peer reviewed); authors state no competing interests and report standard ethical approvals for use of All of Us data. - Details such as effect sizes, per-variant p-values for the significant genes, and replication in external cohorts were not reported in the abstract and must be consulted in the full manuscript or supplementary material.

### 26. [Vision Language Models underperform for detecting Acute Myeloid Leukemia in bone marrow smears](https://medichelpline.com/clinical-feed/medrxiv-17-vision-language-models-fail-to-reliably-detect-acute-myeloid-leukemia-in-bone.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-22
- **Detail Markdown URL:** [Vision Language Models underperform for detecting Acute Myeloid Leukemia in bone marrow smears](https://medichelpline.com/clinical-feed/medrxiv-17-vision-language-models-fail-to-reliably-detect-acute-myeloid-leukemia-in-bone.md)

> **Executive GIST:** - The study evaluated three **Vision Language Models (VLMs)** for zero-shot detection of **Acute Myeloid Leukemia (AML)** on digitized bone marrow smears (BMS). Data comprised whole-slide images from 50 AML patients and 50 bone marrow donors, with ten representative fields of view extracted per sample. - Models tested were two generalist VLMs (Qwen3.5-397B-A17B-FP8 and GLM-4.6V-FP8) and one medically adapted model (Medgemma-27b-it). Two prompting strategies were used: a context-rich prompt asking for WHO/FAB criteria and a minimal context-free prompt. - All models tended to overcall leukemia. With context-rich prompts, GLM-4.6V labeled 90% of leukemic samples as AML but also misclassified 92% of healthy donors as AML. - The medically adapted model MedGemma-27b-it misclassified 86% of healthy donors and correctly detected AML in only 66% of cases under context-rich prompting. - Qwen3.5 performed best with a detailed prompt but still had low specificity (0.26) and overall accuracy 0.51. Under context-free prompting, accuracies improved across models (range 0.47–0.79). - Qwen3.5 maintained the highest specificity (0.64) with context-free prompting, correctly identifying 94% of AML and yielding an overall accuracy of 0.79 in that configuration. - Agreement between model outputs and human expert morphological feature reports was poor for all models, indicating inadequate recognition of cell-level morphologies. - Authors attribute failures to limited hematology image representation in training data; pathology imaging archives and histopathology are more widely scraped than hematologic slides, making hematology an out-of-distribution use case for these VLMs. - Conclusion: Current generalist and the tested medically adapted VLM are unreliable for clinical decision support in hematology and unsuitable for AML detection from BMS in their present form. Data are available on reasonable request; study ethics approvals and informed consent were obtained.

### 27. [Machine Learning-Assisted VTE Risk Assessment from Routine EHR Data](https://medichelpline.com/clinical-feed/medrxiv-7-machine-learning-supported-efficient-vte-risk-assessment-using-routinely.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-19
- **Detail Markdown URL:** [Machine Learning-Assisted VTE Risk Assessment from Routine EHR Data](https://medichelpline.com/clinical-feed/medrxiv-7-machine-learning-supported-efficient-vte-risk-assessment-using-routinely.md)

> **Executive GIST:** - Study analysed 577,904 hospital admissions and 726,896 mandated venous thromboembolism (**VTE**) assessment forms from five NHS hospitals between 2015 and 2025 to evaluate feasibility of automating risk assessment using routinely collected **electronic health record (EHR)** data. - Overall form completion was high (96.7%); timely completion rose from 47.4% in 2015 to 90.5% in 2024, showing major improvement in adherence over time. - Agreement between clinician-completed forms and structured EHR data was good for common risk factors but poor for low-prevalence variables, which were often under-documented on forms. - Despite documentation discrepancies, thrombosis risk derived from assessment forms was associated with higher VTE incidence (odds ratio 3.31, 95% CI 2.81–3.90), supporting clinical validity of the recorded risk. - Machine learning models trained on the first 14 hours of EHR data achieved discrimination similar to clinician-recorded variables (AUROC 0.709 for EHR-based models vs 0.704 for clinician-recorded variables), indicating potential for real-time EHR-integrated pre-population and decision support. - Results support feasibility of EHR-based automation with machine learning to assist point-of-care VTE risk assessment, though some variables remain under-documented and data access was within a secure NHS environment with restrictions. - Ethical approvals and data governance: study used anonymised data under favourable ethics approval (South West - Central Bristol Research Ethics Committee reference 21/SW/0120) and data are available on reasonable request to Imperial Secure Data Environment with restrictions.

### 28. [Retrieval-Augmented LLMs for MedDRA Adverse Event Coding in AML Trials](https://medichelpline.com/clinical-feed/medrxiv-3-retrieval-augmented-large-language-models-for-clinically-aligned-adverse-event.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-18
- **Detail Markdown URL:** [Retrieval-Augmented LLMs for MedDRA Adverse Event Coding in AML Trials](https://medichelpline.com/clinical-feed/medrxiv-3-retrieval-augmented-large-language-models-for-clinically-aligned-adverse-event.md)

> **Executive GIST:** - The study developed a **retrieval-augmented reasoning** pipeline to assign Low-Level Terms (LLTs) from free-text adverse event (AE) reports in acute myeloid leukemia (**AML**) clinical trials, addressing scalability and subjectivity of manual MedDRA coding. - The pipeline used dense semantic retrieval to propose a constrained top-100 candidate LLT list, then applied structured LLM reasoning to select one LLT and deterministically map to Preferred Term (**PT**) and System Organ Class (**SOC**) levels. - LLaMA-3.3-70B-Instruct served as the primary backbone; the framework was benchmarked across several open instruction-tuned LLMs to assess model-dependent effects. - Retrospective evaluation used AE datasets from three prospective AML trials: MOSAIC, DELTA, and DaunoDouble. Both automated string-agreement metrics (LLT/PT/SOC accuracy) and expert-assessed Clinical Correctness Rate (CCR) were reported. - Automated results: LLT exact-string accuracy 50–58%, PT accuracy 78–85%, SOC accuracy 90–93% across datasets. Expert review found high clinical acceptability with CCR between 91% and 97%. - Zero-shot generation and random candidate selection performed substantially worse than the retrieval-augmented approach. Semantic retrieval outperformed lexical similarity retrieval in including coder-assigned LLTs among candidates. - Backbone choice impacted LLT exact agreement more than PT or SOC accuracy, which were relatively stable across models. - The authors emphasize that strict LLT-level string agreement underestimates clinical appropriateness and recommend combining hierarchical automated metrics with clinical expert validation for AI-assisted MedDRA coding in hematology trials. - Ethical oversight was provided by the TU Dresden Ethics Committee (INSPRIME; BO-EK-400092023). Underlying patient-level trial data are not publicly available due to institutional and privacy constraints; aggregated results and supplementary materials are included in the article.

### 29. [Single-cell tRNA Expression Atlas Across Human Hematopoiesis](https://medichelpline.com/clinical-feed/biorxiv-7-single-cell-mapping-of-trna-expression-dynamics-across-human-hematopoiesis.md)
- **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-08-15
- **Detail Markdown URL:** [Single-cell tRNA Expression Atlas Across Human Hematopoiesis](https://medichelpline.com/clinical-feed/biorxiv-7-single-cell-mapping-of-trna-expression-dynamics-across-human-hematopoiesis.md)

> **Executive GIST:** - The authors introduce a scalable, high-throughput method—**sc-STM-seq**—for simultaneous single-cell profiling of **tRNA** and mRNA in individual cells. - sc-STM-seq was applied to human bone marrow to map tRNA expression and splicing across hematopoietic differentiation trajectories. - The study identifies sets of tRNAs associated with **stemness**, general differentiation, and particular blood cell lineages, indicating lineage-specific tRNA programs. - The work produces an atlas of the hematopoietic tRNA landscape, positioning tRNA expression as an additional layer of cellular heterogeneity during human blood development. - The resource and analysis are provided online via a dedicated bioinformatics link for the hematopoietic tRNA atlas. - Competing interests for two authors are disclosed; others declared no competing interests. Funding sources and supporting organizations are listed but detailed cohort/sample numbers are not reported in the abstract.

### 30. [Extended 5‑Day Stability and Sterility of Thawed PF24 After a 6‑Hour Transport Cooler Simulation](https://medichelpline.com/clinical-feed/medrxiv-12-extended-validation-of-transport-conditions-of-thawed-pf24-units.md)
- **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-08-14
- **Detail Markdown URL:** [Extended 5‑Day Stability and Sterility of Thawed PF24 After a 6‑Hour Transport Cooler Simulation](https://medichelpline.com/clinical-feed/medrxiv-12-extended-validation-of-transport-conditions-of-thawed-pf24-units.md)

> **Executive GIST:** - The study evaluated the effect of a simulated **6‑hour cooler** transport on thawed plasma frozen within 24 hours (**PF24**) and then stored for an extended 120‑hour (5‑day) post‑thaw period. - Fourteen PF24 units (8 group O, 6 group B) were thawed and randomized to control (direct refrigeration at 1–6 °C) or experiment arms that included 30 minutes at room temperature and 6 hours in validated transport coolers before refrigeration. - Laboratory measurements taken at 0, 6, 24, and 120 hours post‑thaw included temperature monitoring, prothrombin time (PT), Factor V (FV) activity, and Factor VIII (FVIII) activity. - Sterility testing was performed at 0 and 120 hours using automated aerobic and anaerobic blood culture systems; all cultures showed no growth at 120 hours. - At 120 hours there were no statistically significant differences between control and experiment groups for mean PT (15.09 vs 15.16 s, p = .44), FV activity (81.14% vs 74.57%, p = .23), or FVIII activity (61.86% vs 53.00%, p = .22). - Delta analysis (change from 0 to 120 hours) indicated equivalent coagulation factor decay rates between control and experiment units. - The Institutional Review Board of the University of Arizona waived ethical approval; authors declared no competing interests and reported that all data are contained in the manuscript. - The authors conclude that a **6‑hour cooler** transport period for thawed PF24 does not accelerate coagulation factor degradation or compromise sterility over a 5‑day shelf life, supporting more flexible inventory return policies to reduce waste. - Details not reported in the source include specific cooler temperature ranges during the 6‑hour simulation beyond that temperature was measured, details of statistical methods beyond p values presented, and any clinical outcome data or broader multicenter validation.

## Machine-Readable Pagination & Traversal
- [← Main Clinical Feed Hub](https://medichelpline.com/clinical-feed.md)
- [Next Page (Page 2) →](https://medichelpline.com/clinical-feed/hematology.md?page=2)
## Other Clinical Specialties
- [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- [Dentistry](https://medichelpline.com/clinical-feed/dentistry.md)
- [Public Health](https://medichelpline.com/clinical-feed/public-health.md)
- [Regulatory & FDA](https://medichelpline.com/clinical-feed/regulatory.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.